ATE291919T1 - Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen - Google Patents

Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen

Info

Publication number
ATE291919T1
ATE291919T1 AT00979157T AT00979157T ATE291919T1 AT E291919 T1 ATE291919 T1 AT E291919T1 AT 00979157 T AT00979157 T AT 00979157T AT 00979157 T AT00979157 T AT 00979157T AT E291919 T1 ATE291919 T1 AT E291919T1
Authority
AT
Austria
Prior art keywords
adatanserin
treatment
neurodegenerative diseases
acute neurodegenerative
treating
Prior art date
Application number
AT00979157T
Other languages
English (en)
Inventor
Magid Abdel-Megid Abou-Gharbia
James Edward Barrett
Wayne Everett Childers Jr
John Allen Moyer
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE291919T1 publication Critical patent/ATE291919T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Processing Of Meat And Fish (AREA)
AT00979157T 1999-11-12 2000-11-10 Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen ATE291919T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43921999A 1999-11-12 1999-11-12
PCT/US2000/030973 WO2001034136A2 (en) 1999-11-12 2000-11-10 Use of adatanserin for the treatment of neurodegenerative conditions

Publications (1)

Publication Number Publication Date
ATE291919T1 true ATE291919T1 (de) 2005-04-15

Family

ID=23743796

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00979157T ATE291919T1 (de) 1999-11-12 2000-11-10 Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen

Country Status (22)

Country Link
EP (2) EP1547597A3 (de)
JP (1) JP2003513915A (de)
KR (1) KR100757226B1 (de)
CN (1) CN100469368C (de)
AT (1) ATE291919T1 (de)
AU (1) AU773733B2 (de)
BR (1) BR0015523A (de)
CA (1) CA2390797A1 (de)
CZ (1) CZ298535B6 (de)
DE (1) DE60019166T2 (de)
EA (1) EA006099B1 (de)
ES (1) ES2235998T3 (de)
HK (1) HK1046505B (de)
HU (1) HUP0301847A3 (de)
IL (1) IL149264A0 (de)
MX (1) MXPA02004654A (de)
NO (1) NO322371B1 (de)
NZ (1) NZ518814A (de)
PL (1) PL355014A1 (de)
PT (1) PT1242089E (de)
WO (1) WO2001034136A2 (de)
ZA (1) ZA200204682B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006099B1 (ru) * 1999-11-12 2005-08-25 Уайт Способ лечения острого нейродегенеративного расстройства
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254552A (en) * 1988-05-24 1993-10-19 American Home Products Corporation Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
EA006099B1 (ru) * 1999-11-12 2005-08-25 Уайт Способ лечения острого нейродегенеративного расстройства

Also Published As

Publication number Publication date
NO322371B1 (no) 2006-09-25
HK1046505A1 (en) 2003-01-17
CN1390128A (zh) 2003-01-08
KR100757226B1 (ko) 2007-09-11
AU773733B2 (en) 2004-06-03
DE60019166T2 (de) 2006-05-11
EP1547597A2 (de) 2005-06-29
ZA200204682B (en) 2003-09-11
HK1046505B (en) 2005-06-03
MXPA02004654A (es) 2004-09-10
JP2003513915A (ja) 2003-04-15
WO2001034136A2 (en) 2001-05-17
NO20022187L (no) 2002-05-07
NZ518814A (en) 2005-08-26
BR0015523A (pt) 2002-10-22
DE60019166D1 (de) 2005-05-04
PT1242089E (pt) 2005-08-31
NO20022187D0 (no) 2002-05-07
EP1242089B1 (de) 2005-03-30
HUP0301847A2 (hu) 2003-09-29
WO2001034136A3 (en) 2002-03-21
IL149264A0 (en) 2002-11-10
ES2235998T3 (es) 2005-07-16
PL355014A1 (en) 2004-03-22
CZ20021629A3 (cs) 2003-06-18
EA006099B1 (ru) 2005-08-25
KR20020073132A (ko) 2002-09-19
HUP0301847A3 (en) 2004-01-28
CZ298535B6 (cs) 2007-10-31
CA2390797A1 (en) 2001-05-17
EA200200559A1 (ru) 2002-12-26
EP1242089A2 (de) 2002-09-25
EP1547597A3 (de) 2006-09-27
CN100469368C (zh) 2009-03-18
AU1656701A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE450269T1 (de) Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DK0668763T3 (da) Anvendelse af phenserin til fremstillingen af lægemidler til behandlingen af kognitive sygdomme
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
DE69322957D1 (de) L - Deprenyl zur Behandlung von makulärer Degeneration
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
ATE366581T1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE291919T1 (de) Verwendung von adatanserin zur behandlung von akuten neurodegenerativen erkrankungen
DE69900774D1 (de) Verwendung von topische präparationen mit glyceryl trinitrat und lanolin zur behandlung von erektilen funktionsstörungen
SE9904863D0 (sv) New use
NO971453D0 (no) Anvendelse av bradykinin-antagonister for fremstilling av legemidler for behandling av kroniske fibrogenetiske og akutte leversykdommer
DE69307702D1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
ATE245421T1 (de) Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
RU97110384A (ru) Способ лечения вибрационной болезни
RU94013606A (ru) Гемостимулятор
RU95117774A (ru) Способ лечения хронических воспалительных заболеваний верхних дыхательных путей

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1242089

Country of ref document: EP

REN Ceased due to non-payment of the annual fee